- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 | 1 | GlobeNewswire (USA) | ||
| 05.04. | IO Biotech Appoints Faiçal Miyara Chief Business Officer | 1 | Contract Pharma | ||
| 05.04. | IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer | 271 | GlobeNewswire (Europe) | NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®... ► Artikel lesen | |
| 22.03. | IO Biotech, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 11.03. | IO Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.03. | IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 06.03. | IO Biotech GAAP EPS of -$0.40 misses by $0.02 | 1 | Seeking Alpha | ||
| 05.03. | IO Biotech, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | IO Biotech Announces 2023 Fourth-Quarter and Year-End Results | 24 | GlobeNewswire (Europe) | Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned... ► Artikel lesen | |
| 05.03. | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | IO Biotech to Present at 44th Annual Cowen Health Care Conference | 1 | GlobeNewswire (USA) | ||
| 08.01. | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.12.23 | IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial | 200 | GlobeNewswire (Europe) | NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win®... ► Artikel lesen | |
| 28.11.23 | IOBT and GGE among pre-market losers | 1 | Seeking Alpha | ||
| 27.11.23 | IO Biotech executive discloses purchase of 10K shares | 3 | Seeking Alpha | ||
| 27.11.23 | IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying | 3 | Benzinga.com | ||
| 13.11.23 | IO Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.11.23 | IO Biotech GAAP EPS of -$0.43 misses by $0.10 | 1 | Seeking Alpha | ||
| 13.11.23 | IO Biotech: Q3 Earnings Insights | 1 | Benzinga.com | ||
| 13.11.23 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,986 | +4,45 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,975 | -1,02 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,754 | -3,33 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,960 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 6,660 | -1,19 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,450 | -6,73 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 4,200 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio | HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop... ► Artikel lesen | |
| BIOMEA FUSION | 11,160 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
IO BIOTECH INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
